Comparative Pharmacology
Head-to-head clinical analysis: CAPASTAT SULFATE versus PARASAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPASTAT SULFATE versus PARASAL SODIUM.
CAPASTAT SULFATE vs PARASAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Capastat sulfate (capreomycin) is a cyclic polypeptide antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, interfering with initiation and elongation steps.
Parasal sodium is a prodrug that is converted to 5-aminosalicylic acid (5-ASA) in the colon, where it inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis, thereby exerting anti-inflammatory effects in the gastrointestinal tract.
15 mg/kg (max 1 g) intramuscularly daily for 60-120 days.
300 mg orally twice daily
None Documented
None Documented
3-6 hours; prolonged to 12-24 hours in renal impairment; negligible hepatic metabolism
2-3 hours for low doses (antiplatelet effect); 15-30 hours for high doses (anti-inflammatory), increasing with dose due to saturation of hepatic metabolism.
Primarily renal (80-90% as unchanged drug via glomerular filtration); minor fecal (10-20%)
Primarily renal (90-95% as unchanged drug and metabolites, with 50-70% as unchanged salicylate in alkaline urine); minor biliary (2-5%) and fecal (<1%).
Category C
Category C
Antituberculosis Agent
Antituberculosis Agent